Evidence map›Paper›PMID 38473743›Full record

ReviewInternational journal of molecular sciences2024

Type I IFN in Glomerular Disease: Scarring beyond the STING.

Alexis Paulina Jimenez-Uribe, Steve Mangos, Eunsil Hahm

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. A novel two-hit murine model of viral-primed sepsis-associated acute kidney injury.American journal of physiology. Renal physiology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Alexis Paulina Jimenez-UribeDepartment of Internal Medicine, Division of Nephrology, Rush University Medical Center, Chicago, IL 60612, USA.ORCID 0000-0002-1620-0416
Steve MangosDepartment of Internal Medicine, Division of Nephrology, Rush University Medical Center, Chicago, IL 60612, USA.ORCID 0000-0003-1402-1008
Eunsil HahmDepartment of Internal Medicine, Division of Nephrology, Rush University Medical Center, Chicago, IL 60612, USA.
Rush University Medical Center · US

Funding

Targeting bone marrow to treat renal diseaseR01DK132072 · NIDDK · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Eunsil Hahm, Jochen Reiser · 2023 to 2026
$2.0M
The role of ICOSL in renal protectionR01DK125394 · NIDDK · RUSH UNIVERSITY MEDICAL CENTER · PI HAHM, EUNSIL · 2021 to 2024
$1.4M
NIDDK NIH HHS R01 DK125394NIDDK NIH HHS R01DK125394, R01DK132072NIDDK NIH HHS R01 DK132072
6 · The paper itself

Abstract

The field of nephrology has recently directed a considerable amount of attention towards the stimulator of interferon genes (STING) molecule since it appears to be a potent driver of chronic kidney disease (CKD). STING and its activator, the cyclic GMP-AMP synthase (cGAS), along with intracellular RIG-like receptors (RLRs) and toll-like receptors (TLRs), are potent inducers of type I interferon (IFN-I) expression. These cytokines have been long recognized as part of the mechanism used by the innate immune system to battle viral infections; however, their involvement in sterile inflammation remains unclear. Mounting evidence pointing to the involvement of the IFN-I pathway in sterile kidney inflammation provides potential insights into the complex interplay between the innate immune system and damage to the most sensitive segment of the nephron, the glomerulus. The STING pathway is often cited as one cause of renal disease not attributed to viral infections. Instead, this pathway can recognize and signal in response to host-derived nucleic acids, which are also recognized by RLRs and TLRs. It is still unclear, however, whether the development of renal diseases depends on subsequent IFN-I induction or other processes involved. This review aims to explore the main endogenous inducers of IFN-I in glomerular cells, to discuss what effects autocrine and paracrine signaling have on IFN-I induction, and to identify the pathways that are implicated in the development of glomerular damage.

Indexed as

Interferon Type IVirus DiseasesCicatrixHumansImmunity, InnateInflammationSignal TransductionToll-Like ReceptorsInterferon Type IToll-Like Receptorsglomerular diseasesIFN-I pathwayintracellular pattern-recognition receptorssterile inflammationSTING

Identifiers

PMID38473743
PMCPMC10931919
OpenAlexW4392003531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.